secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-10-20T12:17:31+00:00
Accession:  0001437749-26-032971
Event type: litigation
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Fifth Circuit vacates class certification in Filana securities suit, sends case back to Texas district court
--------------------------------------------------------------------------------

- Fifth Circuit on Oct 16, 2026 vacated the Western District of Texas order granting class certification against Filana Therapeutics and named officers and employees.
- Class had covered all purchasers of Filana securities from September 14, 2020 through October 12, 2023; certification proceedings now proceed on remand.
- Appeals court held the district court misapplied the legal standard, failing to weigh market-inefficiency evidence and improperly rejecting the meme-stock argument.
- Fifth Circuit made no judgment on whether Filana's securities traded in an efficient or inefficient market; no damages figure or settlement disclosed.
- Company had won the right to an interlocutory appeal in October 2025; CFO Eric J. Schoen signed the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774926032971/0001437749-26-032971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774926032971/sava20261019_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer